B. Riley Issues Pessimistic Estimate for Lantheus Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Investment analysts at B. Riley reduced their Q3 2025 EPS estimates for shares of Lantheus in a research report issued to clients and investors on Thursday, March 20th. B. Riley analyst Y. Zhi now anticipates that the medical equipment provider will post earnings of $1.51 per share for the quarter, down from their prior forecast of $1.57. B. Riley currently has a “Buy” rating and a $122.00 target price on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share.

Several other brokerages also recently weighed in on LNTH. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $129.43.

Lantheus Price Performance

Lantheus stock opened at $99.44 on Monday. The business has a fifty day moving average price of $92.77 and a 200-day moving average price of $96.47. Lantheus has a 1-year low of $57.92 and a 1-year high of $126.89. The stock has a market capitalization of $6.81 billion, a price-to-earnings ratio of 16.55 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of LNTH. Janus Henderson Group PLC grew its holdings in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its stake in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Lantheus during the 4th quarter valued at approximately $36,183,000. Finally, Groupama Asset Managment acquired a new position in shares of Lantheus in the 3rd quarter valued at $439,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 over the last quarter. Insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.